Compare CPSH & KRRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CPSH | KRRO |
|---|---|---|
| Founded | 1984 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Building Materials | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 67.6M | 101.1M |
| IPO Year | 1995 | 2019 |
| Metric | CPSH | KRRO |
|---|---|---|
| Price | $4.70 | $11.58 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 12 |
| Target Price | $6.00 | ★ $47.10 |
| AVG Volume (30 Days) | ★ 184.0K | 147.4K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 82.35 |
| EPS | ★ 0.03 | N/A |
| Revenue | N/A | ★ $2,271,000.00 |
| Revenue This Year | $55.87 | $145.97 |
| Revenue Next Year | $19.98 | N/A |
| P/E Ratio | $151.10 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.40 | $5.20 |
| 52 Week High | $6.85 | $55.89 |
| Indicator | CPSH | KRRO |
|---|---|---|
| Relative Strength Index (RSI) | 51.43 | 51.18 |
| Support Level | $3.09 | $10.55 |
| Resistance Level | $4.89 | $15.05 |
| Average True Range (ATR) | 0.36 | 0.86 |
| MACD | -0.05 | -0.07 |
| Stochastic Oscillator | 53.92 | 42.86 |
CPS Technologies Corp provides material solutions to the transportation, automotive, energy, computing/Internet, telecommunications, aerospace, defense, and oil and gas end markets. Its primary material solution is metal matrix composites (MMCs), which are a class of materials consisting of a combination of metal and ceramic. The company designs, manufactures and sells custom MMC components, which manages the performance and reliability of systems in the end markets. It also provides baseplates and housings used in radar, satellite and avionics applications. The company provides lids and heat spreaders used with integrated circuits in Internet switches and routers.
Korro Bio Inc is a biopharmaceutical company with a mission to discover, develop, and commercialize a new class of genetic medicines based on editing RNA, enabling the treatment of both rare and highly prevalent diseases. It is generating a portfolio of differentiated programs that are designed to harness the body's natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, Korro Bio is expanding the reach of genetic medicines by delivering additional precision and tunability.